Sana Biotech rises on FDA clearance to initiate cancer therapy trial

Sana Biotechnology

05/01/2024 18:25

** Shares of cell therapy developer Sana Biotechnology
 SANA.O  rise ~6% to $5.20
    ** Co announces FDA clearance to start human trials of its
CAR T cell therapy in patients with a type of cancer of the
immune system
    ** CAR T therapies generally involve extracting
disease-fighting T-cells from a patient, re-engineering them to
attack cancer and infusing them back into the body
     ** The experimental therapy is initially being explored in
patients that have failed to benefit from therapy directed at
CD-19 gene, co said
    ** Shares of SANA were up 3.3% in 2023

 (Reporting by Sneha  S K)
 ((Sneha.SK@thomsonreuters.com;))